Tovorafenib: Tovorafenib is a type II RAF inhibitor, which was approved by the FDA in 2024 for children 6 months and older with relapsed/refractory low-grade gliomas harboring BRAF V600E mutations or fusions. This evidence concerns the gene BRAF and central nervous system cancer.